AstraZeneca plc (AZN) Stock Rating Reaffirmed by Shore Capital
AstraZeneca plc (LON:AZN)‘s stock had its “hold” rating reaffirmed by stock analysts at Shore Capital in a note issued to investors on Monday.
Several other research analysts have also recently weighed in on the company. Morgan Stanley reaffirmed an “overweight” rating and set a GBX 5,600 ($75.31) target price on shares of AstraZeneca plc in a research note on Friday, June 23rd. UBS AG set a GBX 5,150 ($69.26) target price on AstraZeneca plc and gave the company a “neutral” rating in a research note on Tuesday, June 27th. Kepler Capital Markets reaffirmed a “buy” rating and set a GBX 5,500 ($73.96) target price on shares of AstraZeneca plc in a research note on Monday, June 5th. Liberum Capital reaffirmed a “buy” rating and set a GBX 5,500 ($73.96) target price on shares of AstraZeneca plc in a research note on Monday, June 5th. Finally, Deutsche Bank AG reiterated a “buy” rating and issued a GBX 5,700 ($76.65) price target on shares of AstraZeneca plc in a research report on Monday, June 5th. Three investment analysts have rated the stock with a sell rating, eight have assigned a hold rating and eleven have assigned a buy rating to the company. The company has an average rating of “Hold” and an average price target of GBX 5,111.27 ($68.74).
AstraZeneca plc (AZN) opened at 4888.00 on Monday. The firm’s market capitalization is GBX 61.88 billion. The firm has a 50-day moving average of GBX 4,574.46 and a 200 day moving average of GBX 4,884.61. AstraZeneca plc has a 52 week low of GBX 3,996.00 and a 52 week high of GBX 5,520.00.
COPYRIGHT VIOLATION NOTICE: This story was first published by Watch List News and is owned by of Watch List News. If you are accessing this story on another site, it was copied illegally and reposted in violation of U.S. and international copyright & trademark law. The original version of this story can be viewed at https://www.watchlistnews.com/astrazeneca-plc-azn-stock-rating-reaffirmed-by-shore-capital/1590057.html.
In other news, insider Nazneen Rahman acquired 39 shares of the firm’s stock in a transaction dated Thursday, July 27th. The shares were bought at an average price of GBX 4,370 ($58.77) per share, with a total value of £1,704.30 ($2,291.96).
AstraZeneca plc Company Profile
AstraZeneca PLC (AstraZeneca) is a biopharmaceutical company. The Company focuses on discovery and development of products, which are then manufactured, marketed and sold. The Company focuses on three main therapy areas: Oncology, Cardiovascular & Metabolic Disease (CVMD) and Respiratory, while selectively pursuing therapies in Autoimmunity, Infection and Neuroscience.
Receive News & Ratings for AstraZeneca plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca plc and related companies with Analyst Ratings Network's FREE daily email newsletter.